Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Validates High Throughput Format of Gentronix BlueScreen® Assay

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
BlueScreen-384 provides robust, reproducible, and consistent results.

Gentronix has announced the findings of new research published by GlaxoSmithKline (GSK) on the miniaturization and automation of BlueScreen™ HC; a proprietary assay developed by Gentronix for high throughput genotoxicity testing.

Presented in the peer-reviewed Journal of Biomolecular Screening, the study demonstrates that BlueScreen-384 can reduce the need for costly and time-consuming analogue testing in more traditional genotoxicity methods such as the Ames test.

GSK researchers scaled down the assay for use with 384-microwell plates and available reader technologies in high throughput applications and showed that BlueScreen-384 provided robust, reproducible, and consistent results, supporting its use as a routine genotoxicity screening assay.

Importantly, the research also demonstrated how the exploration of structure-activity relationships around a genotoxic lead molecule could be used to identify non-genotoxic analogues.

BlueScreen HC is an innovative assay from Gentronix, which uses genetically modified, human-derived cells containing the GADD45a gene coupled to Gaussia luciferase to detect the genotoxic effects of compounds with high specificity and sensitivity.

Commenting on the publication, Dr Steve Beasley, Commercial Director at Gentronix, said: “The GSK paper provides valuable insights and independent verification for the scalability of our proven BlueScreen HC technology. Additionally, the successful miniaturization of BlueScreen-384 further opens up possibilities for high throughput genotoxicity measurement across a wide range of industries.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Signs First Japanese Contracted Screening Collaboration with Kowa
Gentronix Ltd. has announced the company's first contracted screening project in Japan, with a major Japanese pharmaceutical manufacturer, Kowa Company, Ltd.
Thursday, October 04, 2012
Gentronix Expands Specialist Sales Team in US and Europe
Expansion of sales teams with the appointments of Dorothy Zelent and Simon Johns.
Friday, February 17, 2012
Gentronix Partner with BioQuanta
The agreement covers the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Thursday, November 10, 2011
Gentronix and Apredica Ally to Create Predictive-Toxicology Service
Joint service offering expected to increase drug development success and the safety of new drugs on the market.
Thursday, June 11, 2009
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos